Ampligen
Phase 3Small molecule
Ampligen is one of 54 small molecule programs targeting Toxicity. It is currently in Phase 3.
2
Indications
6
Total Trials
0
Active Trials
53
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
223 competitors in Toxicity
#DrugCompanyPhaseTrials
1Cytotec
PfizerPhase 3
Curcumin
Merck & Co.Phase 3
Sodium-Selenite
SStanford University
Phase 3
Ampligen
NNational Institute of Allergy and Infectious Diseases (NIAID)
Phase 3
Cysteine Hydrochloride
NovartisPreclinical
Imfinzi
AstraZenecaPreclinical
Cellcept
NovartisPreclinical
Afinitor
NovartisPreclinical
Yervoy
Bristol-Myers SquibbPreclinical
Alecensa
RochePreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Toxicity2 trials
Chronic Fatigue Syndrome1 trial
Primary Peritoneal Cancer1 trial
A Clinical Trial of Autologous Oxidized Tumor Cell Lysate Vaccine For Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Terminated·—·Phase 1/2·NCT01312389·3 enrolled
Infection1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Ampligen. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details